Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cantharidin - Verrica Pharmaceuticals

Next Previous
Drug Profile

Cantharidin - Verrica Pharmaceuticals

Alternative Names: Cantharidin 0.7% topical solution; TO-208; VP 102 - Verrica Pharmaceuticals; VP 103; VP 103 - Verrica Pharmaceuticals; VP-102; YCANTH

Latest Information Update: 27 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verrica Pharmaceuticals
  • Developer Torii Pharmaceutical; Verrica Pharmaceuticals
  • Class Antivirals; Benzofurans; Epoxy compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Serine protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Molluscum contagiosum
  • Phase II Genital warts; Warts

Most Recent Events

  • 15 Nov 2025 Verrica Pharmaceutical announced plans to launch YCANTH Rx, a new non-dispensing pharmacy option, in the fourth quarter of 2025
  • 15 Nov 2025 Verrica Pharmaceuticals plans a phase III trial for Warts in USA(Topical) in 2025
  • 21 Oct 2025 Verrica Pharmaceutical anticipates the regulatory submission to EMA for Molluscum contagiosum (In adolescents, In children, In the elderly, In adults) by the fourth quarter of 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top